Outcome of Repeat Venoarterial Extracorporeal Membrane Oxygenation in Postcardiotomy Cardiogenic Shock
(2021) In Journal of Cardiothoracic and Vascular Anesthesia 35(12). p.3620-3625- Abstract
Objective: Data on patients requiring a second run of venoarterial extracorporeal membrane oxygenation (VA-ECMO) support in patients affected by postcardiotomy cardiogenic shock (PCS) are very limited. The authors aimed to investigate the effect of a second run of VA-ECMO on PCS patient survival. Design: Retrospective analysis of an international registry. Setting: Multicenter study, tertiary university hospitals. Participants: Data on adult PCS patients receiving a second run of VA-ECMO. Measurements and Main Results: A total of 674 patients with a mean age of 62.9 ± 12.7 years were analyzed, and 21 (3.1%) patients had a second run of VA-ECMO. None of them required more than two VA-ECMO runs. The median duration of VA-ECMO therapy was... (More)
Objective: Data on patients requiring a second run of venoarterial extracorporeal membrane oxygenation (VA-ECMO) support in patients affected by postcardiotomy cardiogenic shock (PCS) are very limited. The authors aimed to investigate the effect of a second run of VA-ECMO on PCS patient survival. Design: Retrospective analysis of an international registry. Setting: Multicenter study, tertiary university hospitals. Participants: Data on adult PCS patients receiving a second run of VA-ECMO. Measurements and Main Results: A total of 674 patients with a mean age of 62.9 ± 12.7 years were analyzed, and 21 (3.1%) patients had a second run of VA-ECMO. None of them required more than two VA-ECMO runs. The median duration of VA-ECMO therapy was 135 hours (interquartile range [IQR] 61-226) in patients who did not require a VA-ECMO rerun. In the rerun VA-ECMO group the median overall duration of VA-ECMO therapy was 183 hours (IQR 107-344), and the median duration of the first run was 114 hours (IQR 66-169). Nine (42.9%) of the patients who required a second run of VA-ECMO died during VA-ECMO therapy, whereas five (23.8%) survived to hospital discharge. No differences between patients treated with single or second VA-ECMO runs were observed in terms of hospital mortality and late survival. In patients requiring a second VA-ECMO run, the actuarial survival estimates at three and 12 months after VA-ECMO weaning were 23.8% ± 9.3% and 19.6% ± 6.4%, respectively. Conclusions: Repeat VA-ECMO therapy is a valid treatment strategy for PCS patients. Early and late survivals are similar between patients who have undergone a single or second run of VA-ECMO.
(Less)
- author
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cardiac surgery, complications, ECMO, extracorporeal membrane oxygenation, multiple cannulation, survival
- in
- Journal of Cardiothoracic and Vascular Anesthesia
- volume
- 35
- issue
- 12
- pages
- 3620 - 3625
- publisher
- Elsevier
- external identifiers
-
- scopus:85103954557
- pmid:33838979
- ISSN
- 1053-0770
- DOI
- 10.1053/j.jvca.2021.03.001
- language
- English
- LU publication?
- yes
- id
- 441ccb79-af8f-4cc2-b748-cf7ae9eb0de3
- date added to LUP
- 2021-04-23 07:24:46
- date last changed
- 2024-04-06 02:44:10
@article{441ccb79-af8f-4cc2-b748-cf7ae9eb0de3,
abstract = {{<p>Objective: Data on patients requiring a second run of venoarterial extracorporeal membrane oxygenation (VA-ECMO) support in patients affected by postcardiotomy cardiogenic shock (PCS) are very limited. The authors aimed to investigate the effect of a second run of VA-ECMO on PCS patient survival. Design: Retrospective analysis of an international registry. Setting: Multicenter study, tertiary university hospitals. Participants: Data on adult PCS patients receiving a second run of VA-ECMO. Measurements and Main Results: A total of 674 patients with a mean age of 62.9 ± 12.7 years were analyzed, and 21 (3.1%) patients had a second run of VA-ECMO. None of them required more than two VA-ECMO runs. The median duration of VA-ECMO therapy was 135 hours (interquartile range [IQR] 61-226) in patients who did not require a VA-ECMO rerun. In the rerun VA-ECMO group the median overall duration of VA-ECMO therapy was 183 hours (IQR 107-344), and the median duration of the first run was 114 hours (IQR 66-169). Nine (42.9%) of the patients who required a second run of VA-ECMO died during VA-ECMO therapy, whereas five (23.8%) survived to hospital discharge. No differences between patients treated with single or second VA-ECMO runs were observed in terms of hospital mortality and late survival. In patients requiring a second VA-ECMO run, the actuarial survival estimates at three and 12 months after VA-ECMO weaning were 23.8% ± 9.3% and 19.6% ± 6.4%, respectively. Conclusions: Repeat VA-ECMO therapy is a valid treatment strategy for PCS patients. Early and late survivals are similar between patients who have undergone a single or second run of VA-ECMO.</p>}},
author = {{Yusuff, Hakeem and Biancari, Fausto and Jónsson, Kristján and Ragnarsson, Sigurdur and Dalén, Magnus and Fux, Thomas and Dell'Aquila, Angelo M. and Fiore, Antonio and Perna, Dario Di and Gatti, Giuseppe and Gabrielli, Marco and Juvonen, Tatu and Zipfel, Svante and Bounader, Karl and Perrotti, Andrea and Loforte, Antonio and Lechiancole, Andrea and Pol, Marek and Pettinari, Matteo and De Keyzer, Dieter and Welp, Henryk and Maselli, Daniele and Alkhamees, Khalid and Ruggieri, Vito G. and Mariscalco, Giovanni}},
issn = {{1053-0770}},
keywords = {{cardiac surgery; complications; ECMO; extracorporeal membrane oxygenation; multiple cannulation; survival}},
language = {{eng}},
number = {{12}},
pages = {{3620--3625}},
publisher = {{Elsevier}},
series = {{Journal of Cardiothoracic and Vascular Anesthesia}},
title = {{Outcome of Repeat Venoarterial Extracorporeal Membrane Oxygenation in Postcardiotomy Cardiogenic Shock}},
url = {{http://dx.doi.org/10.1053/j.jvca.2021.03.001}},
doi = {{10.1053/j.jvca.2021.03.001}},
volume = {{35}},
year = {{2021}},
}